利伐沙班在疑似深静脉血栓延迟检查中的安全性与可行性
该前瞻性研究纳入挪威Østfold医院急诊科2015年2月至2018年11月连续就诊的疑似首次或复发性下肢深静脉血栓(DVT)门诊患者,在等待24小时内完成加压超声(CUS)期间给予利伐沙班15 mg每日两次,主要终点为大出血发生率,结果为0%(单侧95%CI <0.4),无患者在延迟CUS期间发生主要并发症(0%;95%CI 0.0-0.6),作者认为该策略安全。
要点
- 疑似DVT患者延迟CUS时使用治疗剂量利伐沙班,大出血发生率为0%(单侧95%CI <0.4)。
- 延迟CUS期间无患者发生主要并发症(0%;95%CI 0.0-0.6)。
- 作者认为对疑似DVT患者延迟CUS最多24小时并使用治疗剂量利伐沙班是安全策略。
核心结论
- 作者认为对疑似DVT患者延迟CUS最多24小时并使用治疗剂量利伐沙班是安全策略。
研究设计与样本
- 前瞻性纳入2015年2月至2018年11月挪威Østfold医院急诊科连续就诊的疑似首次或复发性下肢DVT门诊患者。
- 1653例疑似DVT转诊患者中624例被纳入(37.7%;95%CI 35.4-40.1)。
- 患者出院时给予利伐沙班15 mg每日两次,若D-二聚体≥0.5 mg/L纤维蛋白原等效单位,则在24小时内等待CUS。
主要发现
- 119例患者诊断为DVT(19.1%;95%CI 16.1-22.3)。
- 无大出血事件,观察到的大出血率为0%(单侧95%CI <0.4)。
- 无患者在延迟CUS期间发生主要并发症(0%;95%CI 0.0-0.6)。
关键数值与推荐
- 主要终点为从研究纳入至DVT确诊并继续抗凝治疗,或至服用最后一剂利伐沙班后48小时的大出血事件发生率。
- 次要终点为从出院至诊断静脉血栓栓塞症期间进展性DVT症状或肺栓塞症状/体征的发生率。
- D-二聚体≥0.5 mg/L纤维蛋白原等效单位时,在24小时内等待CUS期间给予利伐沙班15 mg每日两次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Guidelines suggest using empiric low-molecular-weight heparin if the diagnostic workup of deep vein thrombosis (DVT) is expected to be delayed. The role of direct oral anticoagulants for deferred compression ultrasound imaging (CUS) in patients with suspected DVT remains unexplored. The main objective of the study was to assess the safety of deferring CUS with therapeutic doses of rivaroxaban. We prospectively included consecutive outpatients referred to the Emergency Department at Østfold Hospital, Norway, with suspected first or recurrent lower-extremity DVT between February 2015 and November 2018. Patients were discharged with rivaroxaban 15 mg twice daily while awaiting CUS within 24 hours if D-dimer level was ≥0.5 mg/L fibrinogen-equivalent units. The primary outcome was the rate of major bleeding incidents from study inclusion until DVT was confirmed and anticoagulation therapy continued, or otherwise up to 48 hours following administration of the last tablet of rivaroxaban. The secondary outcome was the rate of progressive DVT symptoms or symptoms or signs of pulmonary embolism between hospital discharge until venous thromboembolism was diagnosed. Six hundred twenty-four of 1653 patients referred with suspected DVT were included (37.7%; 95% confidence interval [CI], 35.4-40.1). DVT was diagnosed in 119 patients (19.1%; 95% CI, 16.1-22.3). There were no major bleeding incidents, yielding an observed major bleeding rate of 0% (1-sided 95% CI <0.4). No patients experienced major complications in the interval that CUS was deferred (0%; 95% CI, 0.0-0.6). Deferring CUS for up to 24 hours in patients with suspected DVT with therapeutic doses of rivaroxaban is a safe strategy. This trial was registered at www.clinicaltrials.gov as #NCT02486445.
引用
- Fronas SG, Dahm AEA, Wik HS, et al. Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis. Blood Adv. 2020. PMID: 32502267. doi:10.1182/bloodadvances.2020001556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。